Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL458801 | 0.80 | AKR1B1 (0.36) | AKR1B1 | |
| SCHEMBL30500659 | 0.80 | AKR1B1 (0.36) | AKR1B1 | |
| SCHEMBL31757604 | 0.80 | AKR1B1 (0.36) | AKR1B1 | |
| SCHEMBL22692164 | 0.77 | AKR1B1 (0.40) | AKR1B1 | |
| SCHEMBL310198 | 0.77 | AKR1B1 (0.40) | AKR1B1 | |
| SCHEMBL6048321 | 0.76 | PAX8 (0.39) | PAX8AKR1B1 | |
| SCHEMBL1092322 | 0.76 | PAX8 (0.39) | PAX8AKR1B1 | |
| SCHEMBL9274321 | 0.73 | FDPS (0.32) | PAX8AKR1B1 | |
| SCHEMBL5841143 | 0.70 | TP53 (0.30) | — | |
| SCHEMBL31630521 | 0.69 | TDP1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600740-B2 | Fluorinated N-acetyl glucosamine analogs and xylose derivatives | UTI LIMITED PARTNERSHIP (CA) | 2026-04-14 | — | — | US | disclosed |
| US-12227788-B2 | Compositions, methods and treatments for inhibiting cell adhesion and virus binding and penetration | TUMOREND, LLC (US) | 2025-02-18 | — | — | US | disclosed |
| US-11787844-B2 | Targeting of chondroitin sulfate glycans | VAR2 PHARMACEUTICALS APS (DK) | 2023-10-17 | — | — | US | disclosed |
| US-20220396823-A1 | COMPOSITIONS, METHODS AND TREATMENTS FOR INHIBITING CELL ADHESION AND VIRUS BINDING AND PENETRATION | TUMOREND, LLC (US) | 2022-12-15 | — | — | US | disclosed |
| US-20220332746-A1 | FLUORINATED N-ACETYL GLUCOSAMINE ANALOGS AND XYLOSE DERIVATIVES | UTI LIMITED PARTNERSHIP (CA) | 2022-10-20 | — | — | US | disclosed |
| US-11365212-B2 | Fluorinated N-acetyl glucosamine analogs and xylose derivatives | UTI LIMITED PARTNERSHIP (CA) | 2022-06-21 | — | — | US | disclosed |
| US-11203776-B2 | Compositions, methods and treatments for inhibiting cell adhesion and virus binding and penetration | TUMOREND, LLC (US) | 2021-12-21 | — | — | US | disclosed |
| EP-3087091-B1 | VAR2CSA-DRUG CONJUGATES | ZYMEWORKS INC (CA) | 2021-10-20 | — | — | EP | disclosed |
| US-20210214384-A1 | FLUORINATED N-ACETYL GLUCOSAMINE ANALOGS AND XYLOSE DERIVATIVES | UTI LIMITED PARTNERSHIP (CA) | 2021-07-15 | — | — | US | disclosed |
| CN-104136041-B | Targeted chondroitin sulfate glycans | VAR2制药有限公司 | 2021-06-29 | — | — | CN | disclosed |
| WO-2015095952-A1 | VAR2CSA-DRUG CONJUGATES | THE CENTRE FOR DRUG RESEARCH AND DEVELOPMENT (CA) | 2015-07-02 | — | — | WO | disclosed |
| US-20150004099-A1 | TARGETING OF CHONDROITIN SULFATE GLYCANS | VAR2 PHARMACEUTICALS APS (DK) | 2015-01-01 | — | — | US | disclosed |
| EP-2812024-A1 | TARGETING OF CHONDROITIN SULFATE GLYCANS | Var2 Pharmaceuticals ApS (DK) | 2014-12-17 | — | — | EP | disclosed |
| WO-2013117705-A1 | TARGETING OF CHONDROITIN SULFATE GLYCANS | VAR2 PHARMACEUTICALS APS (DK) | 2013-08-15 | — | — | WO | disclosed |
| US-20060281708-A1 | Fluorinated glucosamine analogs useful for modulating post-translational glyscosylations on cells | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2006-12-14 | — | — | US | disclosed |
| US-7098195-B2 | Fluorinated glucosamine analogs useful for modulating post-translational glycosylations on cells | HEALTH RESEARCH, INC. (US) | 2006-08-29 | — | — | US | disclosed |
| EP-1461046-A4 | FLUORINATED GLUCOSAMINE ANALOGS USEFUL FOR MODULATING POST-TRANSLATIONAL GLYCOSYLATIONS ON CELLS | BRIGHAM & WOMENS HOSPITAL (US) | 2005-06-22 | — | — | EP | disclosed |
| EP-1461046-A2 | FLUORINATED GLUCOSAMINE ANALOGS USEFUL FOR MODULATING POST-TRANSLATIONAL GLYCOSYLATIONS ON CELLS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2004-09-29 | — | — | EP | disclosed |
| WO-2003093410-A2 | FLUORINATED GLUCOSAMINE ANALOGS USEFUL FOR MODULATING POST-TRANSLATIONAL GLYCOSYLATIONS ON CELLS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2003-11-13 | — | — | WO | disclosed |
| US-20030148997-A1 | Fluorinated glucosamine analogs useful for modulating post-translational glycosylations on cells | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220396823-A1 | COMPOSITIONS, METHODS AND TREATMENTS FOR INHIBITING CELL ADHESION AND VIRUS BINDING AND PENETRATION | SIGLEC7, SIGLEC9, HAVCR2 | PAX8 4718/4885AKR1B1 2345/4885 |
| US-11203776-B2 | Compositions, methods and treatments for inhibiting cell adhesion and virus binding and penetration | SIGLEC7, SIGLEC9, HAVCR2 | PAX8 4718/4885AKR1B1 2345/4885 |
| US-11365212-B2 | Fluorinated N-acetyl glucosamine analogs and xylose derivatives | FUT6, FUT5, B3GNT2 | PAX8 1990/4885AKR1B1 1989/4885 |
| US-20060281708-A1 | Fluorinated glucosamine analogs useful for modulating post-translational glyscosylations on cells | B3GAT3, UGGT1, FUT5 | PAX8 4248/4885AKR1B1 3448/4885 |
| US-20220332746-A1 | FLUORINATED N-ACETYL GLUCOSAMINE ANALOGS AND XYLOSE DERIVATIVES | CSGALNACT1, FUT6, FUT5 | PAX8 2233/4885AKR1B1 3454/4885 |
| US-12600740-B2 | Fluorinated N-acetyl glucosamine analogs and xylose derivatives | CSGALNACT1, FUT5, FUT6 | PAX8 2953/4885AKR1B1 3339/4885 |
| US-12227788-B2 | Compositions, methods and treatments for inhibiting cell adhesion and virus binding and penetration | SIGLEC7, SIGLEC9, HAVCR2 | PAX8 4718/4885AKR1B1 2345/4885 |
| US-20030148997-A1 | Fluorinated glucosamine analogs useful for modulating post-translational glycosylations on cells | FUT5, FUT6, OGT | PAX8 4397/4885AKR1B1 3044/4885 |
| US-20210214384-A1 | FLUORINATED N-ACETYL GLUCOSAMINE ANALOGS AND XYLOSE DERIVATIVES | FUT6, FUT5, B3GNT2 | PAX8 1990/4885AKR1B1 1989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.